Eli Chapman, PhD

Dr. Eli Chapman is a key figure in the field of pharmacology and toxicology, serving as an Associate Professor at the University of Arizona Cancer Center. With an impressive academic background, Dr. Chapman completed his PhD in chemistry at The Scripps Research Institute, where he honed his expertise in drug discovery and development. His research is primarily centered on understanding and leveraging molecular chaperones and the NRF2 pathway in cellular quality control and protection mechanisms. At the University of Arizona, Dr. Chapman is an integral part of the Cancer Biology Program and the Cancer Center, where he actively contributes to both research and collaborative efforts. His work is pivotal in advancing our understanding of how cells maintain their integrity and protect themselves from damage, which is crucial for developing new therapeutic strategies. Dr. Chapman's research interests are deeply rooted in exploring the intricate mechanisms of cellular protection and quality control. By focusing on NRF2 and molecular chaperones, he aims to uncover novel drug targets and develop innovative treatments that could potentially revolutionize the way we approach diseases related to cellular stress and damage. In addition to his research, Dr. Chapman is dedicated to mentoring the next generation of scientists. He is actively involved in guiding students and young researchers, fostering an environment of curiosity and innovation. His commitment to education and research excellence makes him a respected and influential figure within the academic community. Through his work, Dr. Chapman continues to push the boundaries of pharmacology and toxicology, contributing valuable insights and advancements to the field. His dedication to understanding cellular mechanisms and developing new drugs holds promise for significant breakthroughs in medical science.